Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 4, 2005, Pages 2110-2116

  Amar, Laurence ^a   Servais, Aude ^a   Gimenez Roqueplo, Anne Paule ^b   Zinzindohoue, Franck ^b   Chatellier, Gilles ^b   Plouin, Pierre François ^a  

^a Hypertension Unit   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METADRENALIN;

ADRENAL TUMOR; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; HUMAN; HYPERTENSION; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RECURRENCE; TIME FACTORS;

EID: 17844405577     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1398     Document Type: Article

References (50)

1. Bravo EL, Tagle R 2003 Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539-553
2. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329
3. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
4. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621
5. Plouin PF, Chatellier G, Fofol I, Corvol P 1997 Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29:1133-1139
6. La Batide-Alanore A, Chatellier G, Plouin PF 2003 Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 21:1703-1707
7. Crout JR, Sjoerdsma A 1964 Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 43:94-102
8. Lenders JWM, Pacak K, Walther MM, Linehan WM, Mannelli J, Friberg J, Reiser HR, Goldstein DS, Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287:1427-1434
9. Feldman JM, Blalock JA, Zern RT, Wells Jr SA 1979 The relationship between enzyme activity and the catecholamine content and secretion of pheochromocytomas. J Clin Endocrinol Metab 49:445-451
10. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent adrenal mass ("incidentaloma") . Ann Intern Med 138:424-429
11. Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison EG 1974 Current management of pheochromocytoma. Ann Surg 179:740-748
12. Melicow MM 1977 One hundred cases of pheochromocytoma (107 tumors) at the Columbia-Presbyterian Medical Center, 1926-1976: a clinicopathological analysis. Cancer 40:1987-2004
13. Mannelli M, Ianni L, Cilotti A, Conti A 1999 Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619-624
14. Héron E, Chatellier G, Billaud E, Foos E, Plouin PF 1996 The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma. Ann Intern Med 125:300-303
15. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G 2001 Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 86:1480-1486
16. Guideline Subcommittee 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 17:151-183
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2002 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 25(Suppl 1):S5-S20
18. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH 1984 Malignant phæochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol (Oxf) 20:189-203
19. Pattarino F, Bouloux PM 1996 The diagnosis of malignant pheochromocytoma. Clin Endocrinol (Oxf) 44:239-241
20. Miller AB, Hoogstraten B, Staquet M, Winkler A 1981 Reporting results of cancer treatment. Cancer 47:207-214
21. Lee JE, Curley SA, Gagel RF, Evans DB, Mickey RC 1996 Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120:1064-1070
22. Modlin IM, Farndon JR, Shepherd A, Johnston ID, Kennedy TL, Montgomery DA, Welbourn RB 1979 Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg 66:456-465
23. Proye C, Verin P, Sautier M, Thevenin D 1989 Pheochromocytoma. Experience of 60 operations. J Urol 95:289-295
24. Orchard T, Grant CS, van Heerden JA, Weaver A 1993 Pheochromocytoma- continuing evolution of surgical therapy. Surgery 114:1153-1158
25. Lucon AM, Pereira MA, Mendonca BB, Halpern A, Wajchenbeg BL, Arap S 1997 Pheochromocytoma: study of 50 cases. J Urol 157:1208-1212
26. Xiao XR, Ye LY, Shi LX, Cheng GF, Li YT, Zhou BM 1998 Diagnosis and treatment of adrenal tumours: a review of 35 years' experience. Br J Urol 82:199-205
27. Hauss J, Moeller A, Bunte H 1985 Adrenalectomy in adrenal hypertension. Cardiology 72:167-173
28. John H, Ziegler WH, Hauri D, Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53:679-683
29. Goldstein RE, O'Neill Jr JA, Holcomb III GW, Morgan III WM, Neblett III WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott Jr HW 1999 Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755-764
30. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC 1999 Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 161:764-767
31. Gaillard DA, Lallemand AV, Moirot HH, Visseaux-Coletto BJ, Paradis PH 1990 Fetal adrenal development during the second trimester of gestation. Pediatr Pathol 10:335-350
32. Klingmuller V, Gurleyen N 1997 Ultrasonic determination of the size of adrenal glands in newborn infants. Ultraschall Med 18:169-173
33. Lam KY, Chan AC, Lo CY 2001 Morphological analysis of adrenal glands: a prospective analysis. Endocr Pathol 12:33-38
34. Kreiner E 1982 Weight and shape of the human adrenal medulla in various age groups. Virchows Arch A Pathol Anat Histol 397:7-15
35. Scott Jr HW, Halter SA 1984 Oncologic aspects of pheochromocytoma: the importance of follow-up. Surgery 96:1061-1066
36. Stenstrom G, Svardsudd K 1986 Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220:225-232
37. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS 1990 Long-term evaluation following resection of apparently benign pheochromocytoma(s) or paraganglioma(s). World J Surg 14:325-329
38. Favia G, Lumachi F, Polistina F, D'Amico DF 1998 Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg 22:689-693
39. Miller WR, Ellis IO, Sainsbury JR, Dixon JM 1994 ABC of breast diseases. Prognostic factors. Br Med J 309:1573-1576
40. O'Riordain DS, Young Jr WF, Grant CS, Carney JA, van Heerden J 1996 Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20:916-921
41. Linnoila RI, Keiser HR, Steinberg SM, Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180
42. Lumachi F, Polistina F, Favia G, D'Amico DF 1998 Extraadrenal and multiple pheochromocytomas. Are there really any differences in pathophysiology and outcome? J Exp Clin Cancer Res 17:303-305
43. de Senanayake P, Denker J, Bravo EL, Graham RM 1995 Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 96:2503-2509
44. Azizi M, Day M, Plouin PF 1994 Localizing value of catecholamine profile in patients with adrenal or ectopic pheochromocytoma. Am J Hypertens 7:110-111
45. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA 1989 Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 7:1720-1725
46. Favier J, Plouin PF, Corvol P, Gasc JM 2002 Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161:235-1246
47. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, European-American Paraganglioma Study Group 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943-951
48. Mulligan LM, Ponder BAJ 1995 Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 80:1989-1995
49. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320
50. Xu W, Mulligan LM, Ponder MA, Liu L, Smith BA, Mathew CG, Ponder BA 1992 Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis. Genes Chromosomes Cancer 4:337-342